Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) shares rose 8.5% during trading on Tuesday . The stock traded as high as $11.55 and last traded at $11.49, with a volume of 55,074 shares. The stock had previously closed at $10.59.

SNDX has been the topic of several research reports. Morgan Stanley raised their price objective on Syndax Pharmaceuticals from $22.00 to $24.00 in a report on Friday, April 8th. Oppenheimer Holdings Inc. restated a “buy” rating and set a $24.00 price objective on shares of Syndax Pharmaceuticals in a report on Tuesday, May 17th. Citigroup Inc. assumed coverage on Syndax Pharmaceuticals in a research report on Monday, March 28th. They set a “buy” rating and a $24.00 target price on the stock. Zacks Investment Research raised Syndax Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, July 5th. Finally, JMP Securities assumed coverage on Syndax Pharmaceuticals in a research report on Monday, March 28th. They set an “outperform” rating and a $28.00 target price on the stock. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $25.00.

The stock’s 50 day moving average is $12.02 and its 200 day moving average is $13.18. The company’s market cap is $202.54 million.

Syndax Pharmaceuticals (NASDAQ:SNDX) last announced its earnings results on Monday, May 16th. The company reported ($2.85) earnings per share for the quarter, missing the consensus estimate of ($0.48) by $2.37. Equities analysts forecast that Syndax Pharmaceuticals Inc. will post ($2.93) earnings per share for the current fiscal year.

Syndax Pharmaceuticals, Inc (Syndax) is a clinical stage biopharmaceutical company developing entinostat as a combination therapy in multiple cancer indications. Syndax is developing entinostat with a focus on tumors that have shown sensitivity to immunotherapy, including lung cancer, melanoma, ovarian cancer and triple-negative breast cancer (TNBC).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.